Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly 2Q Revenues Top $23B | Contract Pharma

What are you searching for?

Sign in
Financial News

Lilly 2Q Revenues Top $23B

Mounjaro and Zepbound drive growth in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly

2Q Revenues: $23.0 billion (+48%)

2Q Earnings: $7.1 billion (+25%)

YTD Revenues: $42.8 billion (+51%)

YTD Earnings: $14.5 billion (+72%)

Comments: Growth in the quarter was driven primarily by Mounjaro and Zepbound. Mounjaro revenue increased 91% to $9.9 billion, and Zepbound revenue increased 44% to $4.9 billion.

Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas grew 121% in the quarter. Ebglyss sales were $201 million, up 131%. Omvoh sales were up 36% to $102 million in the quarter. Jaypirca sales were $192 million, up 56% in the quarter. Kisunla sales reached $167 million, up from $49 million 2Q25. 

Revenue in the U.S. increased 33% to $14.4 billion, and revenue outside the U.S. increased 80% to $8.6 billion. R&D expenses increased 14% to $3.8 billion, or 17% of revenue, driven by continued investments in the company’s early and late-stage portfolio.

By the Numbers: Top 10 Pharma & Biopharma Companies

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics